Last reviewed · How we verify
Truvada Pill
Truvada is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that blocks HIV reverse transcriptase to prevent viral replication.
Truvada is a fixed-dose combination of two nucleoside reverse transcriptase inhibitors that blocks HIV reverse transcriptase to prevent viral replication. Used for HIV pre-exposure prophylaxis (PrEP) in high-risk individuals, HIV-1 infection treatment as part of combination antiretroviral therapy.
At a glance
| Generic name | Truvada Pill |
|---|---|
| Also known as | Tenofovir/Emtricitabine |
| Sponsor | University of North Carolina, Chapel Hill |
| Drug class | Nucleoside reverse transcriptase inhibitor (NRTI) combination |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Truvada contains tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC), which are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase, an enzyme essential for viral replication. When used as pre-exposure prophylaxis (PrEP), it prevents HIV infection in high-risk individuals by maintaining suppressive drug levels in genital and rectal tissues. The combination is also used as part of antiretroviral therapy in HIV-infected patients to suppress viral load.
Approved indications
- HIV pre-exposure prophylaxis (PrEP) in high-risk individuals
- HIV-1 infection treatment as part of combination antiretroviral therapy
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Renal impairment (with long-term use)
- Bone density loss
Key clinical trials
- IPrEP Men's Study: Expanding the Reach of Prevention for Men in Kisumu, Kenya (EARLY_PHASE1)
- Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps) (PHASE3)
- Post-Exposure Prophylaxis in Health Care Workers (PHASE4)
- DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: (PHASE4)
- Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France. (PHASE3)
- Parrying the Pitfalls of PrEP: Project PEACH (PHASE4)
- SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder (PHASE3)
- A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |